-
Synthetic Biologics Surges 25% Amid Positive Phase 2 Data
Wednesday, January 20, 2016 - 9:22am | 252Shares of Synthetic Biologics Inc (NYSE: SYN), a clinical-stage biotechnology company, surged higher by 25 percent at $1.90 early Wednesday morning after the company reported positive topline data from a second Phase 2 clinical trial. Synthetic Biologics stated that its second Phase 2 clinical...